Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that Lespedeza cuneata aqueous extract reduced serum dihydrotestosterone levels and 5α-reductase mRNA expression in testosterone-induced prostatic hyperplasia in rats, suggesting potential as a treatment for prostatic hyperplasia.

This review discusses the clinical features, genetics, and treatment of 21-hydroxylase deficiency, a common type of congenital adrenal hyperplasia, and reports no new research findings.

This study found that α-spinasterol treatment significantly reduced testosterone propionate-induced prostatic hyperplasia in rats, suggesting potential benefits for managing benign prostatic hyperplasia.

This review found that finasteride monotherapy for managing LUTS/BPH significantly reduced prostate volume and improved symptoms, with sexual dysfunctions reported as notable side effects compared to placebo, but emphasizes the need for more comprehensive studies.

This review examines the use of tadalafil and finasteride as a combined therapy for BPH, suggesting it may effectively reduce treatment-related sexual adverse events and improve symptom relief.

This study found that in patients with nonclassical 21-hydroxylase deficiency, genotypes do not reliably predict the severity of hyperandrogenic symptoms, suggesting other genetic factors may influence the phenotype.

This review discusses the fertility and pregnancy challenges faced by women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency and reports no new research findings.

This review discusses the diagnosis and treatment of 21-hydroxylase deficiency in congenital adrenal hyperplasia and emphasizes the need for earlier detection and proper management; it reports no clinical results.

This study found that patients with non-classical 21-hydroxylase deficiency do not appear to be at risk of short adult stature despite increased bone age in childhood.

This research suggests that the enzyme Phospholipase D from E. coli is a strong candidate as the underlying cause of benign prostatic hyperplasia, potentially mediated by its conversion to lysophosphatidic acid in the prostate.

This article discusses advancements and future directions in the treatment of benign prostatic hyperplasia, highlighting ongoing clinical trials of novel techniques, but it reports no new clinical results.

This study concluded that incorporating the percentage of free PSA and urinary markers improves the accuracy of determining the need for prostate biopsy.

Researchers observed that dutasteride and finasteride caused structural changes in the penises of both control and hypertensive rats, with dutasteride having a more pronounced effect on the corpus cavernosum.

This study found that young women with nonclassic congenital adrenal hyperplasia had impaired sexual function and mild depressive symptoms compared to healthy women.

In this study, researchers found that androgen receptor gene polymorphism is associated with higher androgenetic alopecia grades and PSA levels in men with benign prostatic hyperplasia, but not with prostate cancer.

This study found that Monascus cursory extraction reduced baldness, prostate hyperplasia, and tumor incidence in animal models of androgen-related diseases, suggesting it may be a promising new therapeutic candidate.

This case study describes an extremely rare instance of androgen-secreting adrenocortical carcinoma in a patient with non-classical congenital adrenal hyperplasia.

This study identified ten novel compounds that may effectively target steroid 5 alpha-reductase 2 (5αR-2) for potential treatment of benign prostate hyperplasia, exhibiting comparable binding energies to existing drugs like finasteride and dutasteride.

This study shows that measuring 17-hydroxyprogesterone concentrations in scalp hair may be a useful noninvasive tool for monitoring treatment in adults with congenital adrenal hyperplasia.

In this study, children with classical congenital adrenal hyperplasia were found to have increased epicardial fat thickness, which was associated with subclinical atherosclerosis markers and left ventricular dysfunction, especially in poorly controlled cases.

This review discusses the safety of finasteride for male androgenic alopecia and benign prostatic hyperplasia, concluding it remains a viable option due to synergistic effects with other treatments and predictive measures for side effect risk.

This study suggests that measuring scalp hair 17-hydroxyprogesterone and androstenedione concentrations can be a promising tool for monitoring treatment in children with congenital adrenal hyperplasia.

This case report describes a 60-year-old postmenopausal woman with virilization and hirsutism caused by hilus-cell hyperplasia, which was confirmed following bilateral salpingo-oophorectomy.

This animal study found that berberine may alleviate benign prostatic hyperplasia by reducing inflammation and oxidative stress through inhibition of the NF-κB signaling pathway.

This study found that KH053, combining Panax ginseng and bee-pollen, significantly reduced prostate weight and DHT levels, inhibiting BPH development in a rat model.

This study developed a detailed classification system for functional androgenization in females that may enhance diagnosis and personalized treatment by identifying individual dysfunctions.

In this study, the CYP 21A2 gene p.V281L mutation was associated with an increased susceptibility to familial frontal fibrosing alopecia, suggesting an antigen-driven mechanism linked to certain human leukocyte antigen haplotypes.

This case report documents a 3-year-old guinea pig with hormonally active ovarian cysts, cystic endometrial hyperplasia, and bacterial endometritis associated with a uterine foreign body.

This study found that patients with androgenetic alopecia had a higher incidence of metabolic syndrome and benign prostatic hyperplasia compared to those without the condition.

This study observed that adding simvastatin to ongoing metformin treatment reduced certain androgen levels in women with non-classic congenital adrenal hyperplasia and abnormal glucose metabolism, suggesting a potential therapeutic benefit.